» Articles » PMID: 31041312

Immunogenic Cell Death and Immunotherapy of Multiple Myeloma

Overview
Specialty Cell Biology
Date 2019 May 2
PMID 31041312
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

Over the past decades, immunotherapy has demonstrated a prominent clinical efficacy in a wide variety of human tumors. For many years, apoptosis has been considered a non-immunogenic or tolerogenic process whereas necrosis or necroptosis has long been acknowledged to play a key role in inflammation and immune-related processes. However, the new concept of "immunogenic cell death" (ICD) has challenged this traditional view and has granted apoptosis with immunogenic abilities. This paradigm shift offers clear implications in designing novel anti-cancer therapeutic approaches. To date, several screening studies have been carried out to discover ICD inducers and reveal the inherent capacity of a wide variety of drugs to induce cell death-associated exposure of danger signals and to bring about anti-cancer immune responses. Recent shreds of evidence place ER stress at the core of all the scenarios where ICD occur. Furthermore, ER stress and the unfolded protein response (UPR) have emerged as important targets in different human cancers. Notably, in multiple myeloma (MM), a lethal plasma cell disorder, the elevated production of immunoglobulins leaves these cells heavily reliant on the survival arm of the UPR. For that reason, drugs that disrupt ER homeostasis and engage ER stress-associated cell death, such as proteasome inhibitors, which are currently used for the treatment of MM, as well as novel ER stressors are intended to be promising therapeutic agents in MM. This not only holds true for their capacity to induce cell death, but also to their potential ability to activate the immunogenic arm of the ER stress response, with the ensuing exposure of danger signals. We provide here an overview of the up-to-date knowledge regarding the cell death mechanisms involved in situations of ER stress with a special focus on the connections with the drug-induced ER stress pathways that evoke ICD. We will also discuss how this could assist in optimizing and developing better immunotherapeutic approaches, especially in MM treatment.

Citing Articles

Cell death signaling in human erythron: erythrocytes lose the complexity of cell death machinery upon maturation.

Tkachenko A, Havranek O Apoptosis. 2025; .

PMID: 39924584 DOI: 10.1007/s10495-025-02081-5.


Cancer cell-selective induction of mitochondrial stress and immunogenic cell death by PT-112 in human prostate cell lines.

Soler-Agesta R, Moreno-Loshuertos R, Yim C, Congenie M, Ames T, Johnson H J Transl Med. 2024; 22(1):927.

PMID: 39394618 PMC: 11470694. DOI: 10.1186/s12967-024-05739-x.


Identification of a novel immunogenic death-associated model for predicting the immune microenvironment in lung adenocarcinoma from single-cell and Bulk transcriptomes.

Pan X, Chen H, Zhang L, Xie Y, Zhang K, Lian C J Cancer. 2024; 15(16):5165-5182.

PMID: 39247599 PMC: 11375542. DOI: 10.7150/jca.98659.


NIR afterglow nanosystem for photodynamic therapy.

Shu B, Zhao S, Zhang Y, Sun Q, Huang Z RSC Adv. 2024; 14(32):22792-22798.

PMID: 39035721 PMC: 11259105. DOI: 10.1039/d4ra03312d.


CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity.

Naessens F, Demuynck R, Vershinina O, Efimova I, Saviuk M, De Smet G Front Immunol. 2024; 15:1396349.

PMID: 39011040 PMC: 11246865. DOI: 10.3389/fimmu.2024.1396349.


References
1.
Johnson S, Michalak M, Opas M, Eggleton P . The ins and outs of calreticulin: from the ER lumen to the extracellular space. Trends Cell Biol. 2001; 11(3):122-9. DOI: 10.1016/s0962-8924(01)01926-2. View

2.
Deng X, Xiao L, Lang W, Gao F, Ruvolo P, May Jr W . Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem. 2001; 276(26):23681-8. DOI: 10.1074/jbc.M100279200. View

3.
Feng H, Zeng Y, Whitesell L, Katsanis E . Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood. 2001; 97(11):3505-12. DOI: 10.1182/blood.v97.11.3505. View

4.
Reimold A, Iwakoshi N, MANIS J, Vallabhajosyula P, Szomolanyi-Tsuda E, Gravallese E . Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001; 412(6844):300-7. DOI: 10.1038/35085509. View

5.
Brown R, Pope B, Murray A, Esdale W, Sze D, Gibson J . Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 2001; 98(10):2992-8. DOI: 10.1182/blood.v98.10.2992. View